Skip to main content

Table 2 Reverse-engineered HRV14 virus mutants that carry a mutation in VP1 are less susceptible to the antiviral effect of ca603 and pleconaril. Sensitivity to the protease-inhibitor rupintrivir remained unchanged

From: In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses

HRV14IC

ca603

Pleconaril

Rupintrivir

EC50 (μM)

RR

EC50 (μM)

RR

EC50 (μM)

RR

Wild-type

0.014 ± 0.001

/

0.057 ± 0.004

/

0.0058 ± 0.0002

/

VP1_A150V

0.15 ± .0.02*

10

2.3 ± 0.1*

40

0.010 ± 0.001*

2

VP1_A150V_E276K

0.16 ± 0.02*

12

1.6 ± 0.2**

28

0.005 ± 0.0002

1

  1. Activity was determined in a CPE reduction assay with MTS read-out. EC50 = median 50 % effective concentration ± MAD. Data are in duplicate from three independent assays. RR = relative resistance (EC50 of mutated strain / EC50 of wild-type). *p < 0.0001, **p < 0.001
Back to article page

Virology Journal

ISSN: 1743-422X